Clinical trials: Advanced Hodgkin Lymphoma
Lymphoma, Non-Hodgkin, Neoplasms
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Study CC-90010-ST-001 is an open-label, Phase 1a, dose escalation and expansion, First-in-human (FIH) clinical study of CC-90010 in subjects with advanced or unresectable solid tumors and relapsed and/or refractory advanced…
- Trial name
- NCT03220347
- Testing
- CC-90010
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 139 people
- Sponsor
- Celgene
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infections. There are several types of lymphoma.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic
- Trial name
- NCT06120504
- Testing
- PF-08046045
- Where
- 16 sites in United States, Spain
- Volunteers
- 22 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Hodgkin Lymphoma
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin]…
- Trial name
- NCT01712490
- Testing
- brentuximab vedotin, doxorubicin, bleomycin
- Where
- 215 sites in United States, Australia and 19 more
- Volunteers
- 1,334 people
- Sponsor
- Takeda
Malignancies, Solid Malignant Tumor
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase I, multicenter, single-arm, open-label clinical study designed to evaluate the safety and tolerability of JL19001 Injection as monotherapy (Phase Ia) or in combination with standard therapy (Phase Ib) in patients…
- Conditions
- Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer
- Trial name
- NCT07603479
- Testing
- JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM
- Trial name
- NCT02071888
- Testing
- CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Calithera Biosciences, Inc
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to…
- Conditions
- NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer
- Trial name
- NCT03207867
- Testing
- NIR178, PDR001
- Where
- 21 sites in United States, Argentina and 13 more
- Volunteers
- 315 people
- Sponsor
- Novartis Pharmaceuticals
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL)
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies.
- Conditions
- Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04072458
- Testing
- L-Bcl-2 antisense oligonucleotide
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bio-Path Holdings, Inc.
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
The primary objective of this study is to assess the effect of treatment with bendamustine on cardiac repolarization as reflected by the rate-corrected QT interval by the Fridericia method (QTcF).
- Trial name
- NCT01073163
- Testing
- Bendamustine, Rituximab
- Where
- 43 sites in United States, Australia and 1 more
- Volunteers
- 54 people
- Sponsor
- Cephalon
Hematologic Neoplasms, Bone Marrow Neoplasms
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
- Conditions
- Hematologic Neoplasms, Bone Marrow Neoplasms, Non-Hodgkin's Lymphoma
- Trial name
- NCT00421213
- Testing
- Darinaparsin
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Alaunos Therapeutics
Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options.
- Conditions
- Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia, Relapsed/Refractory Myelofibrosis
- Trial name
- NCT03886831
- Testing
- PRT543
- Where
- 23 sites in United States
- Volunteers
- 232 people
- Sponsor
- Prelude Therapeutics Incorporated
Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and…
- Conditions
- Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT05880043
- Testing
- GIC-102
- Where
- 4 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- GI Cell, Inc.
Solid Malignancies, Non-Hodgkin's Lymphoma
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
The purposes of this study are to determine: the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle the side effects of AQ4N when given on the above schedule how much AQ4N is in the…
- Trial name
- NCT00090727
- Testing
- AQ4N
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novacea
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies.
- Trial name
- NCT00670592
- Testing
- HCD122
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Relapsed Advanced Lymphomas
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)
- Trial name
- ADITI-1 (NCT06755450)
- Testing
- AUR112
- Where
- 19 sites in India
- Volunteers
- 40 people
- Sponsor
- Aurigene Discovery Technologies Limited
Advanced Solid Tumors, Non-Hodgkin's Lymphoma
Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
This is a Phase 1, nonrandomized, open-label, dose-escalation study of 3-hour IV infusions of RH-1 administered to patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00558727
- Testing
- RH-1
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Non-Hodgkin Lymphoma, Neoplasms
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
The primary purpose of this open-label study is to investigate the interaction of ketoconazole, a liver enzyme inhibitor, on oral LBH589 in adult patients with advanced solid tumors.
- Trial name
- NCT00503451
- Testing
- LBH589
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals